Overview of Macrol (Roxithromycin)

Quick Facts

Property	Description
Active ingredient	Roxithromycin (INN)
Form	Tablets, film-coated tablets, oral suspension
Pharmacological class	Macrolide antibiotic
General purpose	Managing bacterial infections
Origin	Semi-synthetic compound

Macrol is a prescription-only medicine whose active component is the substance Roxithromycin (INN), which is classified as a macrolide antibiotic. This pharmacological class places the drug within the larger group of antibacterial agents and is clinically recognized for its targeted effect against specific strains of bacteria.

Roxithromycin is a semi-synthetic compound, chemically manufactured by modifying the core structure of the naturally occurring antibiotic, Erythromycin. This modification results in a distinct chemical entity designed to maintain activity against susceptible organisms. Macrol is typically positioned as a single-ingredient product, its identity defined exclusively by the activity of its core compound.

Composition and Available Forms

The active ingredient Roxithromycin is formulated for oral administration and is typically available as both tablets and film-coated tablets, as well as an oral suspension. The composition includes the Roxithromycin active ingredient combined with necessary pharmaceutical excipients.

The availability of multiple dosage forms is a differentiating factor, as the liquid oral suspension is often preferred for pediatric patients who may require precise dosing or easier administration compared to solid medication. The structure of the film-coated tablets is specifically designed to protect the active ingredient until it is absorbed in the digestive tract.

General Therapeutic Purpose

The general purpose of Roxithromycin is to manage bacterial infections by halting the growth and reproduction of bacteria sensitive to this specific class of drug. Its core function is to act as a protein synthesis inhibitor, which prevents bacterial cells from assembling the components necessary for their survival and multiplication.

This function results in a bacteriostatic action, meaning the drug slows the proliferation of the pathogenic bacterial population. By achieving this effect against susceptible organisms, Roxithromycin reduces the overall burden of the infection, allowing the body's natural immune system to effectively clear the remaining bacteria.

What side effects are possible with Macrol (Roxithromycin)?

Possible side effects and safety information

The official safety profile for Roxithromycin, the active ingredient in Macrol, organizes potential effects into frequency categories and affected body systems, as documented by governmental regulatory authorities.

Adverse Reaction Classifications

The most frequently reported adverse reactions are classified as Common, primarily involving Gastrointestinal Disorders such as nausea, vomiting, abdominal pain, and diarrhea. Other Common effects may include headache and dizziness. Adverse reactions with a lower incidence rate are classified as Uncommon or Rare.

Post-marketing reports contribute to the Not Known frequency category, which includes reactions where the incidence rate cannot be accurately estimated from available data. These reports may include specific Blood and Lymphatic System Disorders or severe systemic effects.

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights serious adverse reactions that are rare but clinically significant. These include a potential risk for QT interval prolongation, which is a serious Cardiac Disorder associated with the risk of ventricular arrhythmias, including torsades de pointes.

Severe, potentially life-threatening hypersensitivity reactions such as anaphylaxis and severe cutaneous adverse reactions (Stevens-Johnson syndrome and Toxic Epidermal Necrolysis) are documented and require immediate attention. Hepatobiliary Disorders, including severe cholestatic or acute hepatitis, have also been reported.

Safety constraints noted in official labeling specify that the medicine is generally contraindicated in individuals with severe hepatic impairment. Increased caution is advised for patients with pre-existing risk factors for cardiac arrhythmias. Monitoring of liver function and blood count is noted for patients on prolonged treatment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Roxithromycin overdose focuses on the identification of acute toxicity and mandatory emergency response. If an overdose is suspected, immediate medical attention is required, and individuals must contact a poison control center or go to the nearest hospital Emergency Department.

This immediate action is necessary due to the risk of severe outcomes, which may occur even if there are no current signs of discomfort.

Documented Overdose Manifestations

Overdose presentations typically involve gastrointestinal effects such as severe nausea, vomiting, diarrhea, and epigastric pain, as well as Central Nervous System symptoms like dizziness and headache.

Severe Outcomes and Management

Regulators have documented that excessive ingestion carries the risk of life-threatening cardiotoxicity, including QT interval prolongation and ventricular arrhythmias such as Torsades de pointes. Other severe outcomes include the potential for severe bullous skin reactions.

No specific antidote is known for Roxithromycin overdose. Treatment in a hospital setting is restricted to symptomatic treatment and supportive care. This management may involve procedures such as gastric lavage to remove unabsorbed medication and requires continuous clinical and ECG monitoring.

Therapeutic Uses of Macrol (Roxithromycin)

What Macrol (Roxithromycin) Treats: Main Uses and Benefits

Roxithromycin (Macrol) is applied across domains where symptoms are linked to bacterial infection, providing support that helps ease the overall symptom burden and supports the patient during difficult episodes by easing distress.

The medication is indicated for managing mild to moderately severe infections caused by susceptible organisms. It is commonly used in conditions characterized by acute episodes affecting the respiratory system (including acute pharyngitis, tonsillitis, and community acquired pneumonia), localized skin and soft tissue manifestations (such as impetigo and cellulitis), and specific genitourinary infections (like nongonococcal urethritis caused by Chlamydia).

“The medication is relevant for easing symptoms in clinical settings marked by localized bacterial distress, and assists with maintaining functional stability associated with the infection.”

The medication helps address symptom clusters that may become intense or disruptive, such as severe sore throat, persistent coughing, or painful urination. It is applied when supportive symptom management is appropriate, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Supportive Management for Acute Symptoms
Primary Focus	Conditions involving acute or disruptive bacterial episodes.
Symptom Type	Symptoms related to systemic imbalance and inflammatory states (e.g., fever, localized pain, severe cough).
Clinical Context	Applied in scenarios where additional management of discomfort in outpatient settings is required.
Key Benefit	Supports general well-being during symptomatic periods.

Regulatory References

Medsafe New Zealand Product Data Sheet

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Status

The use of Roxithromycin is defined by specific population eligibility rules documented in regulatory labeling. The medicine is primarily intended for adults and children who meet the minimum age requirements, typically ge 2 months, although this varies by country and formulation. Older adult patients generally do not require a dose adjustment based on age alone.

Absolute Contraindications

Roxithromycin is contraindicated and must not be used in several defined groups:

Classification	Population or Condition
Hypersensitivity	Patients with known allergy to Roxithromycin or any macrolide antibiotic (e.g., Erythromycin).
Organ Impairment	Patients with severe hepatic insufficiency (severe liver disease).
Co-Medication Risk	Patients taking vasoconstrictive ergot alkaloids (e.g., Ergotamine) or certain QT-prolonging drugs (e.g., Cisapride, Pimozide).
Age	Children under 2 months (or 6 months, depending on the label).

Restricted and Conditional Use

Use requires caution and may necessitate monitoring or dose adjustment in other populations. Patients with mild to moderate hepatic impairment must be closely monitored, and a dosage reduction (often by half) is required. Roxithromycin is not recommended during pregnancy or lactation unless the clinical benefit clearly outweighs the potential risks, as its safety in these populations is not fully established, and the drug is excreted into breast milk.

Use also requires caution in patients with uncorrected hypokalemia or hypomagnesemia, or those with existing cardiac conditions that predispose them to QT interval prolongation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Macrol (Roxithromycin) is subject to specific constraints and prohibitions regarding co-administration with other medicines and products, as detailed in official government regulatory documents. The interaction profile is defined by both pharmacokinetic and pharmacodynamic effects.

Formal Contraindications

Regulatory documentation mandates the strict prohibition of Roxithromycin co-administration with vasoconstrictive ergot alkaloids (Ergotamine, Dihydroergotamine) due to the high risk of severe vasoconstriction. Also prohibited are agents like Astemizole, Cisapride, Pimozide, and Terfenadine, as co-use may lead to increased plasma concentrations, posing a risk of QT interval prolongation and serious cardiac arrhythmias.

Exposure Modification

The drug is documented as a weak CYP3A4 inhibitor. This inhibition contributes to an officially observed increase in the AUC of Midazolam and elevated plasma concentrations of Cyclosporine and Theophylline. Co-administration with Warfarin or other Vitamin K antagonists is officially associated with an increase in the International Normalized Ratio (INR).

Timing and Population Notes

To avoid the officially documented decreased absorption, Macrol must be taken on an empty stomach, separated from meals. The potential significance of interactions may be amplified in patients with severe hepatic impairment, as the drug’s half-life is increased, raising the risk of drug accumulation.

Mechanism of Action

Roxithromycin, the active component in Macrol, exerts its action through two distinct mechanistic domains: a primary effect targeting the pathogen and a key secondary effect modulating the host's immune system.

Inhibition of Bacterial Protein Assembly

Roxithromycin functions as a protein synthesis inhibitor by targeting and reversibly binding to the 50S ribosomal subunit of susceptible bacteria. This interaction physically blocks the peptide exit tunnel, which is critical for bacterial growth and replication, leading to a bacteriostatic effect that slows proliferation and enables the host's immune system to operate against the reduced pathogenic load.

Modulation of Host Inflammatory Signaling

Beyond its antibacterial role, Roxithromycin accumulates in host immune cells, such as phagocytes, where it acts as a modulator of inflammatory signaling pathways (e.g., NF-κB). This mechanism dampens the synthesis and release of pro-inflammatory cytokines (chemical mediators), which results in a distinct physiological consequence of reducing excessive or chronic tissue inflammation.

Mechanism Specificity and Constraints

The mechanism is highly specific to the bacterial 50S ribosome and is functionally irrelevant against non-bacterial pathogens like viruses. Its effect can be compromised if bacteria develop resistance, often through modification of the 23S rRNA structure, which physically prevents the drug from binding to its target site.

Dosage and Administration Information

How to Use Macrol (Roxithromycin)

Macrol (Roxithromycin) is intended exclusively for oral administration, typically available in 150 mg and 300 mg film-coated tablets. The procedural use of the medicine is standardized, focusing on specific dosage and timing requirements.

Official Dosing and Frequency

The standard prescribed daily intake for adults is 300 mg per day. This dosage can be administered via two principal regimens:

150 mg taken twice daily (bid)
300 mg taken once daily

The choice between a once-daily or divided dose regimen is based on the specific prescribing context. For children, administration is typically based on weight, with a dosage range of 5 to 8 mg/kg/day divided into two daily doses.

Administration Timing and Duration

For optimal absorption, Roxithromycin tablets must be taken on an empty stomach, which means administering the dose at least 15 minutes before a meal or several hours after eating. The tablets must be swallowed whole with water and should not be crushed or chewed.

The typical course of therapy lasts five to ten days. However, specific labeled constraints require treatment for streptococcal throat infections to continue for a minimum of ten days. If a dose is missed, instructions indicate that the patient should skip the missed dose and resume the normal schedule, avoiding the compensation of a double dose.

Population-Specific Use

The protocol is that the dose must be reduced to 150 mg once daily for patients with documented severe hepatic (liver) impairment. No dosage adjustment is generally required for patients with renal impairment or for older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase I and II Trials: Research Focus and Dosage

Research has investigated the macrolide antibiotic Roxithromycin in early-stage trials, primarily focusing on its safety profile and pharmacokinetics. These studies focused on establishing a safe range of exposure and identifying potential effects in a small number of volunteers. The studies reviewed included research involving a dose of 10mg twice daily, though other regimens have been used.

Controlled Trials: Efficacy and Anti-inflammatory Properties

A number of randomized controlled trials (RCTs) and meta-analyses have explored whether Roxithromycin, when used for conditions beyond typical bacterial infections, showed differences in measured endpoints.

Non-Antibiotic Applications:

Chronic Respiratory Conditions: Studies have examined its use in conditions like bronchiectasis and asthma, focusing on whether it was linked to observed shifts in symptom scores and quality of life. For some chronic respiratory issues, authors noted that Roxithromycin was associated with observed shifts in symptoms and improved quality of life metrics, but often lacked sustained long-term benefit.
Rheumatoid Arthritis (RA): Research has investigated whether the drug's known anti-inflammatory properties, separate from its antibacterial action, were linked to improvements in specific RA disease activity and pain scores over six-month periods in some patient groups.

Safety Profile and Research Gaps

Adverse Events: The investigational drug has been studied across various regimens. Across all trials, specific adverse events that were most frequently reported included mild dizziness, nausea, and fatigue, which are common to the macrolide class. Severe cardiac events were not associated with Roxithromycin use in major cohort studies, unlike some other macrolides.

Research Gaps: Evidence remains limited regarding long-term outcomes beyond 12 weeks of treatment in chronic diseases. Longer-term observational studies are underway, but data on quality of life metrics over six months or more are still pending.

Key Studies & References Arrow – Roxithromycin 150, 150 mg, coated tablets (New Zealand Regulatory Datasheet)

Frequently Asked Questions (FAQ)

Common questions about Macrol (Roxithromycin) (FAQ)

Q: What kind of infections is Macrol (Roxithromycin) officially used to treat?

Official regulatory documentation indicates that Macrol (Roxithromycin) is used to manage mild to moderately severe infections caused by susceptible bacteria. This includes infections in the respiratory tract (upper and lower), specific dental infections, and certain skin and soft tissue infections.

Q: Is Macrol (Roxithromycin) the same kind of antibiotic as penicillin?

No, Macrol (Roxithromycin) is not the same kind of antibiotic as penicillin. Roxithromycin is officially classified as a macrolide antibiotic, which means it belongs to a different pharmacological class and works differently from penicillin.

Q: Why is Macrol (Roxithromycin) sometimes mentioned as an alternative to other common antibiotics?

Regulatory guidance and related literature indicate that Macrol (Roxithromycin) may be used as an alternative for infections where the macrolide class is considered appropriate. This may include its use for patients who have known allergies to penicillins or who cannot use other common antibiotic classes.

Q: How does Macrol (Roxithromycin) compare to Azithromycin in terms of drug class?

According to official sources, both Roxithromycin (the active ingredient in Macrol) and Azithromycin are classified as members of the macrolide antibiotic class of drugs.

Q: Can Macrol (Roxithromycin) be used for a cold or the flu?

Official consumer information states that Macrol (Roxithromycin) is specifically used to treat infections caused by bacteria. The drug is not indicated or studied for viral infections, such as the common cold or the flu.

Q: Are there any specific foods or drinks that should be avoided while using Macrol (Roxithromycin)?

Official regulatory documents indicate that Macrol (Roxithromycin) should be taken on an empty stomach for optimal absorption. This usually means administering the dose at least 15 minutes before or several hours after a meal. No specific food or drink types are universally prohibited in the official prescribing information.

Q: Is it normal to feel a bit nauseous after starting Macrol (Roxithromycin)?

Official safety information lists nausea as a Common adverse reaction. This classification means it is one of the more frequently reported effects noted during the use of Macrol (Roxithromycin).

Q: Can Macrol (Roxithromycin) be used by children?

Yes, official product information includes specific guidelines for the use of Macrol (Roxithromycin) in the pediatric population. Use is typically restricted by a minimum age or weight, such as generally not being recommended for infants under two months.

Q: Is Macrol (Roxithromycin) considered safe for people who are older?

Official guidelines indicate that Macrol (Roxithromycin) can be used in the elderly. Generally, regulatory documents state that no dose adjustment is required based on age alone.

Q: How does Macrol (Roxithromycin) work in the body at a high level?

Macrol (Roxithromycin) works by acting as a protein synthesis inhibitor. This means the drug binds to susceptible bacteria and physically stops them from assembling the necessary components to grow and multiply, which slows the infection.

Q: Is a metallic taste in the mouth sometimes reported with Macrol (Roxithromycin) use?

Adverse reaction reports documented in official sources include the experience of an impaired sense of taste (dysgeusia). This can manifest as an altered or metallic taste while using the medicine.

Q: What do studies say about Macrol (Roxithromycin) and effects on hearing?

Official adverse reaction reports include instances of ringing in the ear (tinnitus) and effects on hearing. However, these effects are typically categorized as low-incidence in the official safety profile.

Q: Are there known long-term side effects associated with Macrol (Roxithromycin) use?

The official safety profile covers the adverse events for typical, short-course uses. Regulatory research summaries indicate that evidence regarding long-term outcomes (specifically beyond 12 weeks of treatment) for chronic diseases is currently limited.

Q: Is Macrol (Roxithromycin) described as a broad-spectrum or narrow-spectrum antibiotic?

Official literature describes Roxithromycin as having an antimicrobial profile similar to erythromycin. It is noted to be active against a range of susceptible micro-organisms, including certain gram-positive, gram-negative, and atypical pathogens.

Q: What evidence is there supporting the use of Macrol (Roxithromycin) for skin infections?

Official regulatory documents indicate Macrol (Roxithromycin) is used for the treatment of skin and skin structure infections when they are caused by micro-organisms that are susceptible to the drug.

Q: Can Macrol (Roxithromycin) lead to antibiotic resistance?

As is true for any antibiotic, the drug's mechanism of action is subject to bacteria developing resistance. This occurs when bacteria modify their structure, which is a factor considered in the use of all antibiotics.

Q: Can Macrol (Roxithromycin) be used for dental infections?

Yes, official regulatory documents indicate Macrol (Roxithromycin) is used for the treatment of specific dental infections that are caused by susceptible micro-organisms.

Q: Can Macrol (Roxithromycin) be used for respiratory tract infections?

Yes, official regulatory documents indicate that Macrol (Roxithromycin) is used for the treatment of both upper respiratory tract infections (like pharyngitis) and lower respiratory tract infections (like acute bronchitis).

Q: Is Macrol (Roxithromycin) typically used for infections in the ears, nose, or throat?

Yes. The official indications explicitly include the treatment of upper respiratory tract infections, which covers common infections affecting the ears, nose, and throat such as sinusitis and tonsillitis.

Q: How quickly is Macrol (Roxithromycin) cleared from the body, based on official data?

Pharmacokinetic data from official reviews indicate that Roxithromycin is eliminated from the body with a half-life of approximately 10 hours in humans.

Q: What information is available regarding Macrol (Roxithromycin) and driving or operating machinery?

Regulatory consumer information notes that users should be aware of how the medicine affects them before engaging in activities like driving or operating machinery.

Q: Is Macrol (Roxithromycin) effective against H. pylori?

Roxithromycin is noted in official literature to be active against certain atypical pathogens, which includes Helicobacter pylori.

Q: What published research findings regarding the effectiveness of Macrol (Roxithromycin) are available?

Published research has investigated Roxithromycin's effectiveness for its core antibacterial uses in controlled trials. Studies have also explored its use for non-antibiotic properties in specific chronic conditions like rheumatoid arthritis and bronchiectasis.

How should Macrol (Roxithromycin) be stored and disposed of?

Storage and Disposal of Macrol (Roxithromycin)

Roxithromycin must be stored according to official regulatory requirements to maintain its stability and prevent accidental exposure.

Storage Conditions

The medicine must be stored below 25 C in a cool, dry place. It is essential to protect Roxithromycin from heat, light, and moisture, such as by avoiding storage in a bathroom. Tablets must remain in their original blister packaging until the time of use. As a mandatory precaution, the medicine must be stored strictly out of the sight and reach of children.

Disposal Instructions

Expired or unused Roxithromycin should be disposed of through a drug take-back program or a pharmacy collection service where available. If no take-back program exists, the medication can be mixed with an undesirable substance, placed in a sealed bag, and discarded with household trash. To prevent environmental release, it is explicitly prohibited to dispose of the product by flushing it down a toilet or pouring it down a drain.

Macrol (Roxithromycin)